Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Pendleton

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Clinics in Chest Medicine|November 5, 2010
Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopeniaRobert C Pendleton, George M Rodgers, Russell D Hull
Expert Review of Clinical Pharmacology|November 26, 2011
Current challenges in personalizing warfarin therapyGwendolyn A McMillin, Sara R Vazquez, Robert C Pendleton
Expert Review of Cardiovascular Therapy|November 27, 2010
Prevention of venous thromboembolism in obesityAndrew L Freeman, Robert C Pendleton, Matthew T Rondina
The Annals of Pharmacotherapy|May 29, 2008
Azathioprine-induced warfarin resistanceSara R Vazquez, Matthew T Rondina, Robert C Pendleton
American Journal of Hematology|May 9, 2012
Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesityAndrew Freeman, Tuesdy Horner, Robert C Pendleton, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 24, 2009
Safety and efficacy of an insulin infusion protocol designed for the non-intensive care settingRussell Vinik, Robert E Jones, Robert C Pendleton, et al.
Hospital Practice (1995)|September 2, 2011
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practiceRyan Wilcox, Robert C Pendleton, Kristi J Smock, et al.
Thrombosis Research|August 2, 2006
The treatment of venous thromboembolism in special populationsMatthew T Rondina, Robert C Pendleton, Michelle Wheeler, et al.
Pharmacotherapy|September 27, 2006
Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolismFreddy M Creekmore, Gary M Oderda, Robert C Pendleton, et al.
Thrombosis Research|March 11, 2009
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patientsMatthew T Rondina, Michelle Wheeler, George M Rodgers, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Clinics in Chest Medicine|November 5, 2010
Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopeniaRobert C Pendleton, George M Rodgers, Russell D Hull
Expert Review of Clinical Pharmacology|November 26, 2011
Current challenges in personalizing warfarin therapyGwendolyn A McMillin, Sara R Vazquez, Robert C Pendleton
Expert Review of Cardiovascular Therapy|November 27, 2010
Prevention of venous thromboembolism in obesityAndrew L Freeman, Robert C Pendleton, Matthew T Rondina
The Annals of Pharmacotherapy|May 29, 2008
Azathioprine-induced warfarin resistanceSara R Vazquez, Matthew T Rondina, Robert C Pendleton
American Journal of Hematology|May 9, 2012
Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesityAndrew Freeman, Tuesdy Horner, Robert C Pendleton, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 24, 2009
Safety and efficacy of an insulin infusion protocol designed for the non-intensive care settingRussell Vinik, Robert E Jones, Robert C Pendleton, et al.
Hospital Practice (1995)|September 2, 2011
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practiceRyan Wilcox, Robert C Pendleton, Kristi J Smock, et al.
Thrombosis Research|August 2, 2006
The treatment of venous thromboembolism in special populationsMatthew T Rondina, Robert C Pendleton, Michelle Wheeler, et al.
Pharmacotherapy|September 27, 2006
Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolismFreddy M Creekmore, Gary M Oderda, Robert C Pendleton, et al.
Thrombosis Research|March 11, 2009
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patientsMatthew T Rondina, Michelle Wheeler, George M Rodgers, et al.
Pageof 4